NICE's final yea and nay to to Lucentis and Avastin
This article was originally published in Scrip
Executive Summary
Roche's VEGF receptor agonist Avastin (bevacizumab) for advanced ovarian cancer is still too expensive for routine use on the National Health Service in England and Wales, says NICE, the health technology appraisal institute. But with the help of a patient access scheme, Novartis helped persuade the institute that its VEGF drug, Lucentis (ranibizumab), is a good use of NHS funds.
You may also be interested in...
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over the use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.